LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Search

Arcutis Biotherapeutics Inc

Abierto

SectorSalud

17.58 1.21

Resumen

Variación precio

24h

Actual

Mínimo

17

Máximo

17.64

Métricas clave

By Trading Economics

Ingresos

9.2M

-16M

Ventas

16M

82M

Margen de beneficio

-19.491

Empleados

342

EBITDA

6.7M

-12M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+30.58% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

342M

2.1B

Apertura anterior

16.37

Cierre anterior

17.58

Noticias sobre sentimiento de mercado

By Acuity

8%

92%

6 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2025, 23:01 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept 2025, 21:59 UTC

Ganancias

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept 2025, 23:39 UTC

Charlas de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept 2025, 21:00 UTC

Ganancias

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept 2025, 18:43 UTC

Charlas de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept 2025, 18:38 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept 2025, 18:20 UTC

Charlas de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept 2025, 18:14 UTC

Charlas de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept 2025, 17:59 UTC

Charlas de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept 2025, 16:51 UTC

Ganancias

Correct: Exor 1H Net Loss -EUR624M

17 sept 2025, 16:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 16:34 UTC

Charlas de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept 2025, 16:25 UTC

Ganancias

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept 2025, 16:23 UTC

Ganancias

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

30.58% repunte

Estimación a 12 meses

Media 22.16 USD  30.58%

Máximo 29 USD

Mínimo 14.29 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

6 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat